According to the latest report by Polaris Market Research, the global blood plasma market size and share was valued at USD 27,861.25 million in 2022 and is anticipated to grow significantly, reaching USD 54,787.67 million by 2032, expanding at a Compound Annual Growth Rate (CAGR) of 7.2% during the forecast period, 2023–2032. The industry’s upward trajectory is fueled by increasing demand for plasma-derived therapies, advancements in medical research, and rising prevalence of chronic and life-threatening diseases worldwide.
Market Overview
Blood plasma plays a critical role in modern medicine, serving as the foundation for producing essential therapies used in treating rare and chronic conditions such as hemophilia, immune deficiencies, and neurological disorders. Plasma-derived products are also widely utilized in surgical procedures, trauma care, and the treatment of infectious diseases. With the rising awareness of therapeutic applications and the growing need for safe and effective plasma-derived medicines, the global market is experiencing steady growth.
The sector’s resilience has been further highlighted during the COVID-19 pandemic, when convalescent plasma therapy emerged as a treatment option. This not only accelerated research activities but also enhanced the recognition of plasma as a life-saving resource.
Key Market Growth Drivers
Rising Prevalence of Chronic Diseases
Increasing cases of rare disorders, immunological diseases, and neurological conditions are significantly driving the demand for plasma-derived therapies. Conditions such as hemophilia A and B, primary immunodeficiency disorders, and Guillain-Barré syndrome are seeing higher diagnosis rates, leading to an expanded market for plasma-based treatments.Advancements in Plasma Collection and Fractionation
Innovations in plasma collection technologies and fractionation processes have improved efficiency and safety. Automated plasmapheresis systems and state-of-the-art storage techniques ensure higher yields and better-quality plasma, boosting the supply chain and meeting global demand.Government and Private Sector Initiatives
Governments and organizations are increasingly investing in infrastructure to improve plasma collection centers and encourage voluntary plasma donation. Public-private collaborations have also enhanced patient access to therapies, particularly in emerging economies.Growing Use of Plasma in Research and Therapeutics
Plasma is not only used in direct therapies but also in research areas such as regenerative medicine and biotechnology. Increasing R&D investments are opening new avenues for its application, further strengthening the market outlook.
??????? ??? ???????? ????????????? ?????? ????:
https://www.polarismarketresearch.com/industry-analysis/global-blood-plasma-market
Market Challenges
While the industry shows promising growth, certain challenges could limit its expansion:
High Cost of Plasma-Derived Therapies: Treatments are expensive, limiting affordability and accessibility, especially in low-income regions.
Stringent Regulatory Environment: Plasma collection and processing must adhere to strict safety standards. Regulatory hurdles often delay product approvals and commercialization.
Limited Donor Pool: Plasma donation rates vary significantly across regions, and maintaining a consistent donor base remains a challenge.
Supply Chain Vulnerabilities: The market is highly dependent on a stable supply of plasma, making it sensitive to disruptions such as pandemics, logistical delays, or geopolitical tensions.
Regional Analysis
North America
North America dominates the global blood plasma market due to well-established healthcare infrastructure, high awareness about plasma therapies, and strong government initiatives. The United States, in particular, accounts for a significant share owing to advanced plasma collection networks and leading market players headquartered in the region.Europe
Europe holds the second-largest share, driven by stringent healthcare regulations, high healthcare spending, and robust research activities. Countries like Germany, the UK, and France are key contributors, with advanced fractionation facilities supporting market growth.Asia-Pacific
Asia-Pacific is projected to be the fastest-growing regional market during the forecast period. Rising healthcare investments, increasing patient population, and growing awareness about plasma donation programs in China, India, and Japan are contributing to this growth.Latin America & Middle East & Africa
These regions are experiencing gradual growth due to improving healthcare infrastructure and rising prevalence of chronic diseases. However, challenges such as limited donor awareness and inadequate infrastructure are slowing market penetration.
Key Companies Operating in the Market
The global blood plasma market is highly competitive, with key players focusing on strategic collaborations, mergers, acquisitions, and product innovations to strengthen their market presence. Major companies include:
Grifols S.A.
CSL Behring
Octapharma AG
Baxter International Inc.
Takeda Pharmaceutical Company Limited
Kedrion S.p.A.
Shire (now part of Takeda)
Biotest AG
China Biologic Products Holdings, Inc.
These companies are heavily investing in expanding plasma collection facilities, advancing fractionation technologies, and diversifying therapeutic offerings to capture a larger share of the growing market.
Future Outlook
The future of the blood plasma market looks promising, with continued growth anticipated across both developed and emerging economies. Increasing investments in biotechnology, stronger donor networks, and broader healthcare access will drive expansion. Furthermore, the integration of artificial intelligence (AI) and digital health tools in plasma collection and supply chain management is expected to enhance operational efficiency.
The industry’s focus on patient-centric approaches, affordability, and accessibility will also be key to sustaining growth. As new therapeutic applications of plasma emerge in regenerative medicine and advanced disease treatments, the sector will continue to expand its global footprint.
Conclusion
The global blood plasma market is set to achieve remarkable growth, reaching nearly USD 54.78 billion by 2032 at a 7.2% CAGR. Rising chronic disease prevalence, growing awareness of plasma therapies, advancements in collection technologies, and expanding applications in healthcare are propelling the industry forward. While challenges such as regulatory barriers and supply chain vulnerabilities persist, strategic initiatives by key players and government support are paving the way for a resilient and innovative market.
More Trending Latest Reports By Polaris Market Research:
Hydrogenated Vegetable Oil Market
